AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender, black race, history of smoking, diabetes, myocardial infarction, stroke, and cancer
Number of subjects: 22576
Study 17610805 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-based self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 17610805 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies targeting postprandial hyperglycemia
Number of subjects: 0
Study 15096971 — intervention group
Group type: EXPERIMENTAL
Intervention: N-13 ammonia (600 MBq or 16 mCi) administered intravenously
Number of subjects: 65
Study 11243303 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 4 mg to 8 mg once daily
Number of subjects: 227
Study 11243303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) 10 mg to 20 mg once daily
Number of subjects: 227
Study 11243303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 227
Study 11243303 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC)
Number of subjects: 227
Study 11243303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 227
Study 9562226 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroid plus theophylline
Number of subjects: 0
Study 9562226 — intervention group
Group type: COMPARATOR
Intervention: Doubling the steroid dose
Number of subjects: 0
Study 8021901 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure (BP) at home for 14 days (mean of 26.7 measurements)
Number of subjects: 503
Study 8021901 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement before and after the two-week period
Number of subjects: 503
Study 8021901 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning self-measured BP
Number of subjects: 503
Study 8021901 — intervention group
Group type: COMPARATOR
Intervention: Second office BP measurement
Number of subjects: 503
Study 2302376 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 40
Study 2302376 — intervention group
Group type: COMPARATOR
Intervention: 0.1% midazolam
Number of subjects: 40
Study 7006616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 51
Study 7006616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30882927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh RBC units
Number of subjects: 100
Study 30882927 — intervention group
Group type: COMPARATOR
Intervention: Standard storage age RBC units
Number of subjects: 100
Study 28576451 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (immediate treatment group)
Number of subjects: 235
Study 28576451 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (deferred treatment group)
Number of subjects: 235
Study 28576451 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 235
Study 28576451 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment group
Number of subjects: 235
Study 26070127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (estriol 50 μg/g gel, twice a week for 12 weeks)
Number of subjects: 31
Study 26070127 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid vaginal gel (once a day for 12 weeks)
Number of subjects: 31
Study 23581825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 40
Study 23581825 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced control condition
Number of subjects: 40
Study 21548209 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil every other day for 12 weeks
Number of subjects: 60
Study 21548209 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E at 100 mg once a day for 12 weeks (Control)
Number of subjects: 60
Study 18949763 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention Program (PIP), n = 60, consisting of eight individual sessions over 4 months.
Number of subjects: 115
Study 18949763 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CG), n = 55.
Number of subjects: 115
Study 18949763 — intervention group
Group type: EXPERIMENTAL
Intervention: PIP (IG)
Number of subjects: 115
Study 17768270 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 80
Study 17768270 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SPT)
Number of subjects: 80
Study 15485728 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted telephone reminder (n=256)
Number of subjects: 703
Study 15485728 — intervention group
Group type: COMPARATOR
Intervention: No reminder (n=242)
Number of subjects: 703
Study 11241060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 20
Study 11241060 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 20
Study 9494478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast material
Number of subjects: 109
Study 9494478 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast material
Number of subjects: 109
Study 8067497 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day for 1 week, then 40 mg/day for 5 weeks)
Number of subjects: 17
Study 8067497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3058752 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse (Corsodyl)
Number of subjects: 14
Study 3058752 — intervention group
Group type: EXPERIMENTAL
Intervention: sanguinarine-zinc mouthrinse (Veadent)
Number of subjects: 14
Study 123880 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteparon forte
Number of subjects: 106
Study 123880 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 106
Study 31006690 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based intervention (Experimental group, n = 23)
Number of subjects: 43
Study 31006690 — intervention group
Group type: COMPARATOR
Intervention: Action focusing intervention (Control group, n = 20)
Number of subjects: 43
Study 28929203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpaste (Colgate Total®)
Number of subjects: 45
Study 28929203 — intervention group
Group type: EXPERIMENTAL
Intervention: Novamin-containing toothpaste (Sensodyne® Repair and Protect)
Number of subjects: 45
Study 28929203 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-containing toothpaste (GD Probiotic Toothpaste®)
Number of subjects: 45
Study 26181252 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 455
Study 26181252 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib
Number of subjects: 455
Study 26181252 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of trastuzumab and lapatinib
Number of subjects: 455
Study 26181252 — intervention group
Group type: EXPERIMENTAL
Intervention: all treatment groups
Number of subjects: 455
Study 23625480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine alone (Group A, n = 46)
Number of subjects: 200
Study 23625480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine and dobutamine (Group B, n = 40)
Number of subjects: 200
Study 23625480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine, dobutamine, and adrenaline (Group C, n = 36)
Number of subjects: 200
Study 23625480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline alone (Group D, n = 32)
Number of subjects: 200
Study 23625480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group E, n = 46)
Number of subjects: 200
Study 20692769 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Number of subjects: 54
Study 20692769 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 54
Study 19420195 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg three times daily for 28 days
Number of subjects: 164
Study 19420195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 16938760 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide therapy
Number of subjects: 40
Study 16938760 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 40
Study 15253732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (6 mg/m2)
Number of subjects: 397
Study 11236072 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg/day
Number of subjects: 401
Study 11236072 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 401
Study 11236072 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 401
Study 11236072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 11236072 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (all doses)
Number of subjects: 401
Study 11236072 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg and 20 mg
Number of subjects: 401
Study 9305229 — intervention group
Group type: EXPERIMENTAL
Intervention: Live active yogurt containing L. acidophilus (225 g twice daily)
Number of subjects: 15
Study 9305229 — intervention group
Group type: COMPARATOR
Intervention: Control group (yogurt without L. acidophilus)
Number of subjects: 15
Study 9305229 — intervention group
Group type: EXPERIMENTAL
Intervention: Live active yogurt containing L. acidophilus
Number of subjects: 15
Study 7906085 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge loaded with gentamicin
Number of subjects: 20
Study 7906085 — intervention group
Group type: COMPARATOR
Intervention: PMMA beads loaded with gentamicin
Number of subjects: 20
Study 3084344 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel rest with parenteral nutrition
Number of subjects: 47
Study 3084344 — intervention group
Group type: COMPARATOR
Intervention: Oral diet
Number of subjects: 47
Study 29385769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 63
Study 29385769 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study 25277730 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 172
Study 25277730 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 172
Study 25277730 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 172
Study 25495543 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and coping strategies incorporated into standard care in cardiac rehabilitation
Number of subjects: 0
Study 25495543 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation program (control group)
Number of subjects: 0
Study 25495543 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and coping strategies
Number of subjects: 0
Study 22795063 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate potassium cold blood cardioplegia (K+, 10 mmol/L)
Number of subjects: 68
Study 22795063 — intervention group
Group type: COMPARATOR
Intervention: High potassium cold blood cardioplegia (K+, 20 mmol/L)
Number of subjects: 68
Study 20361464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 19477776 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation treatment
Number of subjects: 0
Study 19477776 — intervention group
Group type: COMPARATOR
Intervention: Literature on female breast cancer patients treated with hormones
Number of subjects: 0
Study 16158696 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Practice
Number of subjects: 30
Study 16158696 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Practice
Number of subjects: 30
Study 16158696 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 12520156 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III comprehensive cardiac rehabilitation (CR) for 6 months
Number of subjects: 38
Study 12520156 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 38
Study 10393675 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 565
Study 10393675 — intervention group
Group type: COMPARATOR
Intervention: Patients assigned to angioplasty who never underwent the procedure
Number of subjects: 565
Study 10393675 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from enrollment to first balloon inflation
Number of subjects: 565
Study 8695998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic phototherapy
Number of subjects: 0
Study 8695998 — intervention group
Group type: COMPARATOR
Intervention: White light phototherapy
Number of subjects: 0
Study 8695998 — intervention group
Group type: COMPARATOR
Intervention: Blue light phototherapy
Number of subjects: 0
Study 1852979 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks oral digoxin administration
Number of subjects: 14
Study 1852979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6334320 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base as enteric coated pellets (2 X 250 mg)
Number of subjects: 12
Study 6334320 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate tablet (1 X 500 mg)
Number of subjects: 12
Study 6334320 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate sachet (1 X 500 mg)
Number of subjects: 12
Study 31745048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implant anchorage system
Number of subjects: 20
Study 31745048 — intervention group
Group type: COMPARATOR
Intervention: Conventional accentuated compensating curve archwire
Number of subjects: 20
Study 30470323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Pain Course)
Number of subjects: 471
Study 30470323 — intervention group
Group type: COMPARATOR
Intervention: Medically unexplained etiology
Number of subjects: 471
Study 30470323 — intervention group
Group type: COMPARATOR
Intervention: Medically explained etiology
Number of subjects: 471
Study 27631178 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol supplementation (25 µg) plus hypocaloric diet
Number of subjects: 73
Study 27631178 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus hypocaloric diet
Number of subjects: 73
Study 23682797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification including supervised exercise sessions
Number of subjects: 35
Study 23682797 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 21950736 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 × 200 mg)
Number of subjects: 82
Study 21950736 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (2 × 100 mg)
Number of subjects: 82
Study 21950736 — intervention group
Group type: COMPARATOR
Intervention: Prolonged wakefulness
Number of subjects: 82
Study 20659063 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimbursement of smoking cessation support (SCS)
Number of subjects: 0
Study 17614214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials based on the transtheoretical model
Number of subjects: 1044
Study 17614214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials for smokers in precontemplation
Number of subjects: 1044
Study 17614214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials for smokers in contemplation, preparation, action, and maintenance
Number of subjects: 1044
Study 17614214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring for precontemplation
Number of subjects: 1044
Study 15663566 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorofluorocarbon‐driven beclomethasone diproprionate (BDP) 400 microg b.i.d.
Number of subjects: 0
Study 15663566 — intervention group
Group type: COMPARATOR
Intervention: Hydrofluoroalkane‐driven BDP, 200 microg b.i.d.
Number of subjects: 0
Study 12398790 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal assessment by a study nurse
Number of subjects: 33000
Study 12398790 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted assessment based on pre-determined problems
Number of subjects: 33000
Study 12398790 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by primary care team (PC)
Number of subjects: 33000
Study 12398790 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by multidisciplinary geriatric assessment team (GM)
Number of subjects: 33000
Study 12398790 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33000
Study 9792578 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment (continuous positive airway pressure)
Number of subjects: 20
Study 9792578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CPAP pressure during T2 to T4
Number of subjects: 20
Study 9792578 — intervention group
Group type: COMPARATOR
Intervention: Daytime alertness
Number of subjects: 20
Study 7706024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-on-yellow (B-Y) perimetry
Number of subjects: 60
Study 7706024 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow-on-yellow (Y-Y) perimetry
Number of subjects: 60
Study 7706024 — intervention group
Group type: EXPERIMENTAL
Intervention: White-on-white (W-W) perimetry
Number of subjects: 60
Study 7706024 — intervention group
Group type: COMPARATOR
Intervention: Posterior subcapsular cataract
Number of subjects: 60
Study 7706024 — intervention group
Group type: COMPARATOR
Intervention: Anterior cortical cataract
Number of subjects: 60
Study 2654321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 0
Study 2654321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 65221 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP and ABDV chemotherapy with local radiotherapy
Number of subjects: 37
Study 30352537 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral morphine administration
Number of subjects: 0
Study 30352537 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28723689 — intervention group
Group type: EXPERIMENTAL
Intervention: Benifuuki tea
Number of subjects: 32
Study 28723689 — intervention group
Group type: EXPERIMENTAL
Intervention: Yabukita tea
Number of subjects: 32
Study 28723689 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 32
Study 25448102 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 105
Study 25448102 — intervention group
Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 105
Study 23333117 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (carboplatin and paclitaxel)
Number of subjects: 1528
Study 23333117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with standard chemotherapy
Number of subjects: 1528
Study 21659011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal nail fixation (group 1)
Number of subjects: 31
Study 21659011 — intervention group
Group type: COMPARATOR
Intervention: Locked volar plate fixation (group 2)
Number of subjects: 31
Study 17512159 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment period before treatment entry
Number of subjects: 577
Study 17512159 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment entry period
Number of subjects: 577
Study 16502748 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues (high-contrast transverse lines on the floor)
Number of subjects: 14
Study 16502748 — intervention group
Group type: COMPARATOR
Intervention: Auditory cues (rhythmic sounds matching average step time)
Number of subjects: 14
Study 16502748 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 14
Study 14746787 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting calcification cases
Number of subjects: 50
Study 14746787 — intervention group
Group type: COMPARATOR
Intervention: Control cases
Number of subjects: 50
Study 11713727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal graft (ADG) on one peritonsillar fossa
Number of subjects: 10
Study 11713727 — intervention group
Group type: COMPARATOR
Intervention: No treatment on the control side
Number of subjects: 10
Study 9142567 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for one month
Number of subjects: 30
Study 9142567 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual routine)
Number of subjects: 30
Study 8004613 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for younger or premenopausal women
Number of subjects: 0
Study 8004613 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for older or postmenopausal women with estrogen receptor-positive tumors
Number of subjects: 0
Study 8004613 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (general)
Number of subjects: 0
Study 8004613 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 0
Study 3555968 — intervention group
Group type: EXPERIMENTAL
Intervention: bufexamac (20 mg)
Number of subjects: 40
Study 3555968 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone (40 mg)
Number of subjects: 40
Study 29980233 — intervention group
Group type: EXPERIMENTAL
Intervention: hemodynamic monitoring using hTEE technology
Number of subjects: 500
Study 29980233 — intervention group
Group type: COMPARATOR
Intervention: standard hemodynamic monitoring (central venous catheter, pulmonary artery catheter, or conventional echocardiography)
Number of subjects: 500
Study 27932628 — intervention group
Group type: COMPARATOR
Intervention: non‐testimonial text warning labels
Number of subjects: 924
Study 27932628 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐testimonial PWL
Number of subjects: 924
Study 27932628 — intervention group
Group type: EXPERIMENTAL
Intervention: image only testimonial PWL
Number of subjects: 924
Study 27932628 — intervention group
Group type: EXPERIMENTAL
Intervention: image + personal details testimonial PWL
Number of subjects: 924
Study 26187674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 8719
Study 26187674 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 8719